Snakebit Angion reports another miss for lead program, as biotech prepares to shift its 'primary focus'
Angion’s lead organ damage drug took two strikes earlier this year, flopping as a repurposed effort for Covid-19 and whiffing in high-risk kidney transplant patients. The biotech reported a third on Thursday, raising serious questions about the program’s future.
In a Phase II study looking at some cardiac surgery patients at risk of kidney injury, Angion reported its ANG-3777 candidate missed badly on the primary endpoint. The results come about a month and a half after the kidney transplant study and less than five months after the Covid-19 trial, ostensibly leaving the candidate on the chopping block.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
